Recently, the attention has been pointed out on another citrullinated antibody, the antimodified citrullinated vimentin (anti-MCV); changes in serum levels of this antibody correlate with changes in atherogenic ratios (total cholesterol/HDL-C and LDL-C/HDL-C), apolipoprotein A-I, and carotid IMT, thus becoming a possible marker of subclinical atherosclerosis in RA [50]. The gene discussed is APOA1; the disease is rheumatoid arthritis.